ATM Inhibitor KU-55933 Overcomes Ferroptosis-Resistance in Human Cancer Cell Lines
Abstract
Ferroptosis is an iron-dependent form of regulated cell death, and its resistance represents a major obstacle in cancer therapy. In this study, we evaluated the responsiveness of human lung and renal cancer cell lines to ferroptosis inducers and investigated whether pharmacological inhibition of ataxia-telangiectasia mutated (ATM) kinase could overcome ferroptosis resistance. While A549, ACHN, and Caki-1 cells exhibited dose-dependent sensitivity to erastin, RSL3, and FIN56, PC-9 and Caki-2 cells were relatively resistant. Notably, pharmacological inhibition of ATM using KU-55933 significantly sensitized these resistant cells to all tested ferroptosis inducers. This combinatorial treatment induced a DNA damage response, as evidenced by increased γ-H2AX expression, and reduced cell viability in a ferroptosis-dependent manner, which was reversed by ferroptosis inhibitors (ferrostatin-1 and liproxstatin-1) or an iron chelator, deferoxamine. Mechanistically, ATM inhibition disrupted glutathione (GSH) homeostasis in resistant cells. Although single treatments had minimal effects, the combination of erastin and KU-55933 led to a marked depletion of total GSH and reduced GSH, an increase in oxidized glutathione (GSSG), and a significant reduction in the GSH/GSSG ratio. These findings indicate that ATM inhibition promotes ferroptosis by impairing redox balance rather than directly modulating ferroptosis-inducing pathways. Collectively, our results demonstrate that pharmacological ATM inhibition by KU-55933 overcomes ferroptosis resistance by inducing a DNA damage response and disrupting GSH-dependent redox homeostasis. Targeting ATM may represent a promising therapeutic strategy to sensitize resistant cancers to ferroptosis-based treatments.
Related
- CBX3 Deletion Overcomes Ferroptosis Resistance in Colorectal Cancer by Targeting IFNγ/SLC7A11/SLC3A2 Axis
- Targeting SLC1A5-mediated glutamine metabolism overcomes PARP inhibitor resistance in ovarian cancer.
- Targeting oxidative phosphorylation with lixumistat overcomes PARP inhibitor resistance in ovarian cancer
- ESCRT-dependent YAP degradation by AKT blockade overcomes adaptive resistance to RAS(ON) inhibition in pancreatobiliary cancer
- Sitagliptin, a repurposed diabetes drug, overcomes gemcitabine resistance in pancreatic cancer via ribonucleotide reductase inhibition: SITGEM-CARE phase 2 trial.
BibTeX
@article{farooq2026inhibitor,
title = {{ATM Inhibitor KU-55933 Overcomes Ferroptosis-Resistance in Human Cancer Cell Lines}},
author = {Muhammad Irshad Farooq and Mahiro Uozumi and Sisca Ucche and Hiroshi Kitamura and So-Ichiro Sasaki and Yoshihiro Hayakawa},
journal = {Biological and Pharmaceutical Bulletin},
year = {2026},
month = oct,
doi = {10.1248/bpb.b26-00309},
url = {https://www.jstage.jst.go.jp/article/bpb/49/10/49_b26-00309/_article},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - ATM Inhibitor KU-55933 Overcomes Ferroptosis-Resistance in Human Cancer Cell Lines
AU - Muhammad Irshad Farooq
AU - Mahiro Uozumi
AU - Sisca Ucche
AU - Hiroshi Kitamura
AU - So-Ichiro Sasaki
AU - Yoshihiro Hayakawa
PY - 2026
DA - 2026/10/28
JO - Biological and Pharmaceutical Bulletin
DO - 10.1248/bpb.b26-00309
UR - https://www.jstage.jst.go.jp/article/bpb/49/10/49_b26-00309/_article
AB - Ferroptosis is an iron-dependent form of regulated cell death, and its resistance represents a major obstacle in cancer therapy. In this study, we evaluated the responsiveness of human lung and renal cancer cell lines to ferroptosis inducers and investigated whether pharmacological inhibition of ataxia-telangiectasia mutated (ATM) kinase could overcome ferroptosis resistance. While A549, ACHN, and Caki-1 cells exhibited dose-dependent sensitivity to erastin, RSL3, and FIN56, PC-9 and Caki-2 cells were relatively resistant. Notably, pharmacological inhibition of ATM using KU-55933 significantly sensitized these resistant cells to all tested ferroptosis inducers. This combinatorial treatment induced a DNA damage response, as evidenced by increased γ-H2AX expression, and reduced cell viability in a ferroptosis-dependent manner, which was reversed by ferroptosis inhibitors (ferrostatin-1 and liproxstatin-1) or an iron chelator, deferoxamine. Mechanistically, ATM inhibition disrupted glutathione (GSH) homeostasis in resistant cells. Although single treatments had minimal effects, the combination of erastin and KU-55933 led to a marked depletion of total GSH and reduced GSH, an increase in oxidized glutathione (GSSG), and a significant reduction in the GSH/GSSG ratio. These findings indicate that ATM inhibition promotes ferroptosis by impairing redox balance rather than directly modulating ferroptosis-inducing pathways. Collectively, our results demonstrate that pharmacological ATM inhibition by KU-55933 overcomes ferroptosis resistance by inducing a DNA damage response and disrupting GSH-dependent redox homeostasis. Targeting ATM may represent a promising therapeutic strategy to sensitize resistant cancers to ferroptosis-based treatments.
SN - 1347-5215
SN - 0918-6158
ER -